CL2007002606A1 - Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e - Google Patents

Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e

Info

Publication number
CL2007002606A1
CL2007002606A1 CL200702606A CL2007002606A CL2007002606A1 CL 2007002606 A1 CL2007002606 A1 CL 2007002606A1 CL 200702606 A CL200702606 A CL 200702606A CL 2007002606 A CL2007002606 A CL 2007002606A CL 2007002606 A1 CL2007002606 A1 CL 2007002606A1
Authority
CL
Chile
Prior art keywords
acid
halobenzarilar
echrolid
earrollaroar
cianobenzoic
Prior art date
Application number
CL200702606A
Other languages
English (en)
Spanish (es)
Inventor
G Almstead Peter Seongwoo Neil
Original Assignee
Ptc Therapeutics Inc Soc Organ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc Soc Organ filed Critical Ptc Therapeutics Inc Soc Organ
Publication of CL2007002606A1 publication Critical patent/CL2007002606A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL200702606A 2006-09-08 2007-09-07 Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e CL2007002606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
CL2007002606A1 true CL2007002606A1 (es) 2008-04-18

Family

ID=38935880

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702606A CL2007002606A1 (es) 2006-09-08 2007-09-07 Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e

Country Status (24)

Country Link
US (2) US7678922B2 (enExample)
EP (1) EP2059513B1 (enExample)
JP (2) JP5955494B2 (enExample)
KR (1) KR101466368B1 (enExample)
CN (1) CN101535284B (enExample)
AR (3) AR062715A1 (enExample)
AU (1) AU2007292915B2 (enExample)
BR (1) BRPI0716996B8 (enExample)
CA (2) CA2662749C (enExample)
CL (1) CL2007002606A1 (enExample)
DK (1) DK2059513T3 (enExample)
ES (1) ES2404348T3 (enExample)
IL (1) IL197445A (enExample)
MX (1) MX2009002439A (enExample)
MY (1) MY148598A (enExample)
NZ (2) NZ598012A (enExample)
PE (2) PE20120669A1 (enExample)
PL (1) PL2059513T3 (enExample)
PT (1) PT2059513E (enExample)
RU (1) RU2495030C2 (enExample)
TW (1) TWI482761B (enExample)
UA (1) UA99265C2 (enExample)
WO (1) WO2008030570A1 (enExample)
ZA (1) ZA200901782B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP2387995A1 (en) * 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
NZ598012A (en) * 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
UA99600C2 (en) 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR20170100072A (ko) 2006-10-12 2017-09-01 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
TW201729807A (zh) 2015-10-30 2017-09-01 Ｐｔｃ治療公司 用於治療癲癇的方法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
KR20210151131A (ko) 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
CN114920667B (zh) * 2022-06-30 2024-06-21 湖南大学 一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CN1691944A (zh) * 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
AU2006235115C1 (en) * 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
NZ598012A (en) * 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Also Published As

Publication number Publication date
PE20120669A1 (es) 2012-06-01
AU2007292915B2 (en) 2012-07-26
BRPI0716996A2 (pt) 2013-10-08
US20080139818A1 (en) 2008-06-12
AU2007292915A1 (en) 2008-03-13
CA2662749C (en) 2015-01-20
RU2495030C2 (ru) 2013-10-10
PL2059513T3 (pl) 2013-06-28
JP2010502715A (ja) 2010-01-28
WO2008030570A1 (en) 2008-03-13
JP2014193896A (ja) 2014-10-09
DK2059513T3 (da) 2013-05-06
NZ598012A (en) 2013-08-30
AR118922A2 (es) 2021-11-10
HK1134094A1 (en) 2010-04-16
PT2059513E (pt) 2013-04-30
CA2842625C (en) 2016-07-12
EP2059513B1 (en) 2013-01-23
US7678922B2 (en) 2010-03-16
MX2009002439A (es) 2009-03-27
KR20090054464A (ko) 2009-05-29
US8367841B2 (en) 2013-02-05
KR101466368B1 (ko) 2014-11-27
CA2662749A1 (en) 2008-03-13
CN101535284B (zh) 2014-12-10
US20100063297A1 (en) 2010-03-11
TW200823180A (en) 2008-06-01
CA2842625A1 (en) 2008-03-13
PE20080771A1 (es) 2008-06-13
NZ575511A (en) 2012-02-24
ZA200901782B (en) 2010-06-30
CN101535284A (zh) 2009-09-16
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
RU2009113019A (ru) 2010-10-20
ES2404348T3 (es) 2013-05-27
JP5955494B2 (ja) 2016-07-20
BRPI0716996B8 (pt) 2021-05-25
EP2059513A1 (en) 2009-05-20
AR062715A1 (es) 2008-11-26
IL197445A0 (en) 2009-12-24
TWI482761B (zh) 2015-05-01
UA99265C2 (ru) 2012-08-10
IL197445A (en) 2014-01-30
MY148598A (en) 2013-05-15

Similar Documents

Publication Publication Date Title
DK2059513T3 (da) Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
BRPI0719896A2 (pt) Processo para a preparação de alcanolamidas de ácidos graxos
EP2298750A4 (en) NOVEL ISOXAZOLE DERIVATIVE
BRPI0911759A2 (pt) microorganismo para a produção de ácido metacrílico
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
NO2015014I1 (no) Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
SI2546224T1 (sl) Postopek izdelave fluoriranih organskih spojin
IL226395A0 (en) Process for producing aqueous chlorous acid solution for use as bactericide
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
CL2008002417A1 (es) Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria
BRPI0812807A2 (pt) Método para a produção de um medicamento que contem tadafila
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
HN2012000182A (es) Formulacion farmaceutica
EP2356593A4 (en) PROVIDE A NEW LOOK WITH SEARCH RESULTS
CL2007003177A1 (es) Composicion acuosa curable que comprende un aducto de polimero de carbohidrato y agente de entrecruzamiento multifuncional seleccionado entre acido polibasico monomero, su sal, anhidrido y mezclas; metodo para formar composicion acuosa curable; produ
BRPI1007619A2 (pt) "sistema para prevenção de quedas adequado para ser usado por um usuário e métoddo de operação de um sistema para prevenção de quedas que seja usado pelo usuário"
EG26479A (en) Method of treating marine sediments and use of theresulting solid product in mortars or concretes
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
CO6970617A2 (es) Composición herbicida que contiene ciertos ácidos piridina carboxílicos y el ácido (2,4-diclorofenoxi) acético
BRPI0821656A2 (pt) Processo para a geração de uma massa em fusão de aço contendo até 30% de manganês
BRPI0915365A2 (pt) Processo para a preparação de 2-triflúor-metil-5-alquil-piridinas substituídas na posição 1
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
BRPI0808173A2 (pt) método para a produção de cloreto de ácido carboxílico.
FI20065089A0 (fi) Menetelmä yhdistelmäsuolen valmistamiseksi